Stock Events

Stock Events

Greenwich LifeSciences 

$24.2
0
+$1.7+7.56% Today

Statistics

Day High
24.2
Day Low
23.31
52W High
-
52W Low
-
Volume
2,318
Avg. Volume
-
Mkt Cap
335.29M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25MayExpected
Q3 2025
Q4 2025
Next
-0.36
-0.35
-0.33
-0.32
Expected EPS
-0.33
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-31.58MNet Income

Analyst Ratings

$50.00Average Price Target
The highest estimate is 50.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLSI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Puma Biotechnology
PBYI
Mkt Cap256.89M
Puma Biotechnology focuses on the development and commercialization of drugs for the treatment of various forms of cancer, directly competing with GLSI's cancer treatment research.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including oncology.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is a global healthcare company that offers cancer treatments, directly competing with GLSI's focus on breast cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb is a global biopharmaceutical company whose portfolio includes cancer treatments, competing in the same therapeutic areas as GLSI.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG engages in the pharmaceuticals and diagnostics business worldwide, including cancer treatment solutions that compete with GLSI's offerings.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including for cancer, competing with GLSI.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotechnology company that develops and produces human therapeutics, with a focus on oncology treatments that compete with GLSI's products.
Novartis
NVS
Mkt Cap237.61B
Novartis AG focuses on the development and marketing of healthcare products to prevent and treat diseases, including cancer, directly competing with GLSI's research and products.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions, including cancer therapies that compete with GLSI.

About

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Show more...
CEO
ISIN
US3968791083

Listings

XNAS
US
GLSI
BOATS
BOATS
GLSI.BOATS

0 Comments

Share your thoughts

FAQ

What is Greenwich LifeSciences stock price today?▼
The current price of GLSI.BOATS is $24.2 USD — it has increased by +7.56% in the past 24 hours. Watch Greenwich LifeSciences stock price performance more closely on the chart.
What is Greenwich LifeSciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Greenwich LifeSciences stocks are traded under the ticker GLSI.BOATS.
What is Greenwich LifeSciences market cap?▼
Today Greenwich LifeSciences has the market capitalization of 335.29M
When is the next Greenwich LifeSciences earnings date?▼
Greenwich LifeSciences is going to release the next earnings report on May 25, 2026.
What were Greenwich LifeSciences earnings last quarter?▼
GLSI.BOATS earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.32 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Greenwich LifeSciences revenue for the last year?▼
Greenwich LifeSciences revenue for the last year amounts to 0 USD.
What is Greenwich LifeSciences net income for the last year?▼
GLSI.BOATS net income for the last year is -31.58M USD.
When did Greenwich LifeSciences complete a stock split?▼
Greenwich LifeSciences has not had any recent stock splits.